For a child who is short but otherwise healthy, years of growth hormone shots add only modest height on average: about 4 centimeters, or roughly 1.5 inches, to adult height in the randomized trials, with wide differences from child to child. Growth hormone is approved in the United States for this situation, called idiopathic short stature, but pediatric endocrinologists still regard it as a judgment call rather than a routine fix. The most useful first step for a worried parent is a proper growth evaluation, because many short children are simply late bloomers or have short parents.
Start with the growth chart, not the prescription
MedlinePlus’s page on short stature says that most of the time there is no medical cause. Some children have what providers call constitutional growth delay: they grow at a normal pace, start puberty later than their friends, keep growing after peers stop and usually end up about as tall as their parents. If one or both parents are short, a child will most likely be short too. Less often, short stature is a sign of something treatable, such as celiac disease, an underactive thyroid, other chronic illness or growth hormone deficiency, which is diagnosed with specialized growth hormone stimulation tests.
MedlinePlus advises contacting your child’s provider if your child seems much shorter than most children the same age or appears to have stopped growing. A pattern of measurements over time tells more than any single height.
What “idiopathic short stature” means on a label
Somatropin, the medicine version of human growth hormone, is a 191-amino-acid polypeptide hormone identical in sequence to the one made by the pituitary gland, according to the Genotropin prescribing information on DailyMed; the UniProt record for somatotropin shows the natural sequence. The label limits the idiopathic short stature indication to children whose height is at or below 2.25 standard deviations under the average for age and sex, roughly the shortest 1 percent, whose growth rate makes a normal adult height unlikely, whose growth plates are still open, and in whom other causes of short stature have been ruled out.
What the trials show about height gain
A 2017 review by pediatric endocrinologists Antonella Deodati and Stefano Cianfarani traces this use to a 1983 trial and FDA approval in 2003. In the pooled analysis of randomized trials they summarize, treated children ended up 0.65 standard deviations taller than untreated children, about 4 centimeters; in nonrandomized studies the difference was about 3 centimeters. They noted that no single high-quality randomized trial has followed children all the way to adult height, that the benefit is smaller than in conditions such as true growth hormone deficiency, and that individual responses vary widely. Age at the start of treatment, the dose used, length at birth, the gap between a child’s height and the parents’ heights, and delayed bone age were among the reported predictors of adult height.
The reviewers left open whether treatment is worthwhile once you weigh the height gained against its effect on well-being, the burden on children and parents, possible side effects, cost and family expectations. The 2016 Pediatric Endocrine Society guideline likewise describes idiopathic short stature as a controversial indication and asks clinicians to weigh risks and benefits for each child.
Side effects the label asks families to watch for
Treatment means injections under the skin on a regular schedule, and the height results above come from years of therapy. The Genotropin label lists warnings that families can act on:
- Headache with vision changes, nausea or vomiting, which can signal raised pressure around the brain; it usually appears within the first eight weeks and resolves when treatment is stopped or reduced. The label calls for an eye exam before treatment starts.
- A new limp or hip or knee pain, which can be a sign of a slipped growth plate at the hip.
- Worsening of an existing spinal curve, and changes in blood sugar or thyroid function that need periodic checks.
- Persistent, severe belly pain, which should prompt a check for pancreatitis.
Questions to bring to the endocrinologist
Ask what is causing your child’s short stature and what adult height is predicted without treatment. If growth hormone is offered, ask how much gain is realistic for your child specifically, how long treatment would last, how response will be judged after the first year, what your insurance will cover, and what happens if the gain is small. A clear answer to those questions is worth more than an average from a trial.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the linked sources (fetched 2026-10-06 PT). Not medical advice.
Sources
- MedlinePlus Medical Encyclopedia: Short stature
- MedlinePlus Lab Tests: Growth Hormone Tests
- DailyMed: Genotropin (somatropin) prescribing information
- Deodati A, Cianfarani S. The Rationale for Growth Hormone Therapy in Children with Short Stature. Journal of Clinical Research in Pediatric Endocrinology, 2017.
- Grimberg A, et al. Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Hormone Research in Paediatrics, 2016.
- UniProt: Somatotropin (P01241)